Baird analyst Eric Coldwell downgraded Medpace (NASDAQ: MEDP) from Outperform to Neutral with a price target of $349.00 (from $413.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE